Decision-theoretic designs for small trials and pilot studies: A review

Statistical Methods in Medical Research

Volumn 25, Issue 3, 2016, Pages 1022-1038

  Hee, Siew Wan ^a   Hamborg, Thomas ^a   Day, Simon ^b   Madan, Jason ^a   Miller, Frank ^c   Posch, Martin ^d   Zohar, Sarah ^e   Stallard, Nigel ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b Clinical Trials Consulting and Training Limited   (United Kingdom)

^c STOCKHOLM UNIVERSITY   (Sweden)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e INSERM   (France)

Author keywords

Bayesian decision theory; optimal clinical trial design; phase II clinical trials; utility functions

Indexed keywords

CLINICAL TRIAL (TOPIC); DECISION MAKING; DECISION THEORETIC METHOD; DECISION THEORY; DRUG DEVELOPMENT; DRUG RESEARCH; METHODOLOGY; PILOT STUDY; REVIEW; STUDY DESIGN; BAYES THEOREM; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PROCEDURES;

BAYES THEOREM; CLINICAL TRIALS, PHASE II AS TOPIC; DECISION THEORY; HUMANS; PILOT PROJECTS; RESEARCH DESIGN;

EID: 84971012212     PISSN: 09622802     EISSN: 14770334     Source Type: Journal    
DOI: 10.1177/0962280215588245     Document Type: Review

References (102)

1. Lancaster GA, Dodd S, Williamson PR,. Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract 2004; 10: 307-312.
2. Arnold DM, Burns KEA, Adhikari NKJ, et al. The design and interpretation of pilot trials in clinical research in critical care. Crit Care Med 2009; 37: S69-S74.
3. Arain M, Campbell MJ, Cooper CL, et al. What is a pilot or feasibility study? A review of current practice and editorial policy. BMC Med Res Methodol 2010; 10: 67.
4. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Med Res Methodol 2010; 10: 1.
5. Pocock SJ,. Clinical trials: a practical approach, Chichester: Wiley, 1983.
6. Julious SA,. Sample sizes for clinical trials, Boca Raton: CRC Press, 2008.
7. EMA. Guideline on clinical trials in small populations. European Medicines Agency CHMP/EWP/83561/2005, http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003615.pdf (2006, accessed 29 October 2014).
8. EMA. Concept paper on extrapolation of efficacy and safety in medicine development. European Medicines Agency EMA/129698/2012, http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2013/04/WC500142358.pdf (2013, accessed 29 October 2014).
9. Institute of Medicine. Small clinical trials: issues and challenges. National Academy Press, http://www.nap.edu/catalog/10078.htm (2001, accessed 29 October 2014).
10. Casali PG, Bruzzi P, Bogaerts J, et al. Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. Ann Oncol 2015; 26 (2): 300-306.
11. DeGroot M,. Optimal statistical decisions, New York: Wiley, 1970.
12. Raiffa H, Schlaifer R,. Applied statistical decision theory, Boston: MIT Press, 1977.
13. Smith JQ,. Decision analysis: a Bayesian approach, London: Chapman and Hall, 1988.
14. Lindley DV,. The choice of sample size. J Royal Stat Soc: Ser D (The Statistician) 1997; 46: 129-138.
15. Brockwell AE, Kadane JB,. A gridding method for Bayesian sequential decision problems. J Computat Graphic Statist 2003; 12: 566-584.
16. Kadane J, Vlachos P,. Hybrid methods for calculating optimal few-stage sequential strategies: Data monitoring for a clinical trial. Stat Comput 2002; 12: 147-152.
17. Elsevier. Scopus Content Overview, http://www.elsevier.com/online-tools/scopus/content-overview (accessed 20 October 2014).
18. Banerjee A, Tsiatis AA,. Adaptive two-stage designs in phase II clinical trials. Stat Med 2006; 25: 3382-3395.
19. Brunier HC, Whitehead J,. Sample sizes for phase II clinical trials derived from Bayesian decision theory. Stat Med 1994; 13: 2493-2502.
20. Chen C, Beckman RA,. Optimal cost-effective designs of phase II proof of concept trials and associated go-no go decisions. J Biopharm Stat 2009; 19: 424-436.
21. Chen C, Sun L, Li CL,. Evaluation of early efficacy endpoints for proof-of-concept trials. J Biopharm Stat 2013; 23: 413-424.
22. Chen Y, Smith BJ,. Adaptive group sequential design for phase II clinical trials: A Bayesian decision theoretic approach. Stat Med 2009; 28: 3347-3362.
23. Ding M, Rosner GL, Müller P,. Bayesian optimal design for phase II screening trials. Biometrics 2008; 64: 886-894.
24. Hee SW, Stallard N,. Designing a series of decision-theoretic phase II trials in a small population. Stat Med 2012; 31: 4337-4351.
25. Jung SH, Lee T, Kim KM, et al. Admissible two-stage designs for phase II cancer clinical trials. Stat Med 2004; 23: 561-569.
26. Lai TL, Liao OYW, Zhu RG,. Adaptation in clinical development plans and adaptive clinical trial designs. Statist Interf 2012; 5: 431-442.
27. Nixon RM, O'Hagan A, Oakley J, et al. The rheumatoid arthritis drug development model: A case study in Bayesian clinical trial simulation. Pharm Stat 2009; 8: 371-389.
28. Pallay A,. A decision analytic approach to a futility analysis of a phase II pharmaceutical study. J Biopharm Stat 2001; 11: 209-225.
29. Palmer CR,. A comparative phase II clinical trials procedure for choosing the best of three treatments. Stat Med 1991; 10: 1327-1340.
30. Rossell D, Müller P, Rosner GL,. Screening designs for drug development. Biostatistics 2007; 8: 595-608.
31. Stallard N,. Approximately optimal designs for phase II clinical studies. J Biopharm Stat 1998; 8: 469-487.
32. Stallard N,. Sample size determination for phase II clinical trials based on Bayesian decision theory. Biometrics 1998; 54: 279-294.
33. Stallard N,. Decision-theoretic designs for phase II clinical trials allowing for competing studies. Biometrics 2003; 59: 402-409.
34. Stallard N,. Optimal sample sizes for phase II clinical trials and pilot studies. Stat Med 2012; 31: 1031-1042.
35. Stallard N, Posch M, Friede T, et al. Optimal choice of the number of treatments to be included in a clinical trial. Stat Med 2009; 28: 1321-1338.
36. Stallard N, Thall PF,. Decision-theoretic designs for pre-phase II screening trials in oncology. Biometrics 2001; 57: 1089-1095.
37. Stallard N, Thall PF, Whitehead J,. Decision theoretic designs for phase II clinical trials with multiple outcomes. Biometrics 1999; 55: 971-977.
38. Staquet M, Sylvester R,. A decision theory approach to phase II clinical trials. Biomedicine 1977; 26: 262-266.
39. Sylvester RJ,. A Bayesian approach to the design of phase II clinical trials. Biometrics 1988; 44: 823-836.
40. Sylvester RJ, Staquet MJ,. Design of phase II clinical trials in cancer using decision theory. Cancer Treat Rep 1980; 64: 519-524.
41. Thall PF, Nguyen HQ, Braun TM, et al. Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes. Biometrics 2013; 69: 673-682.
42. Trippa L, Rosner GL, Müller P,. Bayesian enrichment strategies for randomized discontinuation trials. Biometrics 2012; 68: 203-211.
43. Zhao L, Taylor JM, Schuetze SM,. Bayesian decision theoretic two-stage design in phase II clinical trials with survival endpoint. Stat Med 2012; 31: 1804-1820.
44. Zhao L, Woodworth G,. Bayesian decision sequential analysis with survival endpoint in phase II clinical trials. Stat Med 2009; 28: 1339-1352.
45. Berry DA, Ho CH,. One-sided sequential stopping boundaries for clinical trials: A decision-theoretic approach. Biometrics 1988; 44: 219-227.
46. Chen MH, Willan AR,. Determining optimal sample sizes for multistage adaptive randomized clinical trials from an industry perspective using value of information methods. Clin Trials 2013; 10: 54-62.
47. Cheng Y, Berry DA,. Optimal adaptive randomized designs for clinical trials. Biometrika 2007; 94: 673-687.
48. Cheng Y, Shen Y,. Bayesian adaptive designs for clinical trials. Biometrika 2005; 92: 633-646.
49. Cheng Y, Shen Y,. An efficient sequential design of clinical trials. J Stat Plan Inference 2013; 143: 283-295.
50. Cheng Y, Su F, Berry DA,. Choosing sample size for a clinical trial using decision analysis. Biometrika 2003; 90: 923-936.
51. Chernoff H, Petkau AJ,. Sequential medical trials involving paired data. Biometrika 1981; 68: 119-132.
52. Claxton K, Posnett J,. An economic approach to clinical trial design and research priority-setting. Health Econ 1996; 5: 513-524.
53. Claxton K, Thompson KM,. A dynamic programming approach to the efficient design of clinical trials. J Health Econ 2001; 20: 797-822.
54. Eckermann S, Willan AR,. Expected value of information and decision making in HTA. Health Econ 2007; 16: 195-209.
55. Gittins J, Pezeshk H,. How large should a clinical trial be? J Royal Stati Soc: Ser D (The Statistician) 2000; 49: 177-187.
56. Gittins J, Pezeshk H,. A behavioral Bayes method for determining the size of a clinical trial. Drug Inf J 2000; 34: 355-363.
57. Gittins JC, Pezeshk H,. A decision theoretic approach to sample size determination in clinical trials. J Biopharm Stat 2002; 12: 535-551.
58. Halpern J, Brown Jr BW, Hornberger J,. The sample size for a clinical trial: A Bayesian-decision theoretic approach. Stat Med 2001; 20: 841-858.
59. Heitjan DF, Houts PS, Harvey HA,. A decision-theoretic evaluation of early stopping rules. Stat Med 1992; 11: 673-683.
60. Hornberger J, Eghtesady P,. The cost-benefit of a randomized trial to a health care organization. Control Clin Trials 1998; 19: 198-211.
61. Jennison C, Turnbull BW,. Interim monitoring of clinical trials: Decision theory, dynamic programming and optimal stopping. Kuwait J Sci 2013; 40: 43-59.
62. Jiang F, Lee JJ, Müller P,. A Bayesian decision-theoretic sequential response-adaptive randomization design. Stat Med 2013; 32: 1975-1994.
63. Kikuchi T, Gittins J,. A behavioral Bayes method to determine the sample size of a clinical trial considering efficacy and safety. Stat Med 2009; 28: 2293-2306.
64. Kikuchi T, Gittins J,. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy nd safety: Imbalanced sample size in treatment groups. Stat Methods Med Res 2011; 20: 389-400.
65. Kikuchi T, Pezeshk H, Gittins J,. A Bayesian cost-benefit approach to the determination of sample size in clinical trials. Stat Med 2008; 27: 68-82.
66. Lewis RJ, Berry DA,. Group sequential clinical trials: A classical evaluation of Bayesian decision-theoretic designs. J Am Stat Assoc 1994; 89: 1528-1534.
67. Lewis RJ, Lipsky AM, Berry DA,. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: A frequentist evaluation. Clin Trial 2007; 4: 5-14.
68. Maroufy V, Marriott P, Pezeshk H,. An optimization approach to calculating sample sizes with binary responses. J Biopharm Stat 2014; 24: 715-731.
69. Mehta CR, Patel NR,. Adaptive, group sequential and decision theoretic approaches to sample size determination. Stat Med 2006; 25: 3250-3269.
70. Orawo LA, Christen JA,. Bayesian sequential analysis for multiple-arm clinical trials. Stat Comput 2009; 19: 99-109.
71. Patel NR, Ankolekar S,. A Bayesian approach for incorporating economic factors in sample size design for clinical trials of individual drugs and portfolios of drugs. Stat Med 2007; 26: 4976-4988.
72. Patel NR, Ankolekar S, Antonijevic Z, et al. A mathematical model for maximizing the value of phase 3 drug development portfolios incorporating budget constraints and risk. Stat Med 2013; 32: 1763-1777.
73. Pezeshk H, Gittins J,. A fully Bayesian approach to calculating sample sizes for clinical trials with binary responses. Drug Inf J 2002; 36: 143-150.
74. Pezeshk H, Nematollahi N, Maroufy V, et al. The choice of sample size: A mixed Bayesian/frequentist approach. Stat Meth Med Res 2009; 18: 183-194.
75. Pezeshk H, Nematollahi N, Maroufy V, et al. Bayesian sample size calculation for estimation of the difference between two binomial proportions. Stat Meth Med Res 2013; 22: 598-611.
76. Wang YG,. Gittins indices and constrained allocation in clinical trials. Biometrika 1991; 78: 101-111.
77. Wathen JK, Christen JA,. Implementation of backward induction for sequentially adaptive clinical trials. J Computat Graphic Stat 2006; 15: 398-413.
78. Wathen JK, Thall PF,. Bayesian adaptive model selection for optimizing group sequential clinical trials. Stat Med 2008; 27: 5586-5604.
79. Willan AR,. Optimal sample size determinations from an industry perspective based on the expected value of information. Clin Trial 2008; 5: 587-594.
80. Willan AR, Eckermann S,. Optimal clinical trial design using value of information methods with imperfect implementation. Health Econ 2010; 19: 549-561.
81. Willan AR, Eckermann S,. Value of information and pricing new healthcare interventions. Pharmacoeconomics 2012; 30: 447-459.
82. Willan AR, Kowgier M,. Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods. Clin Trial 2008; 5: 289-300.
83. Willan AR, Pinto EM,. The value of information and optimal clinical trial design. Stat Med 2005; 24: 1791-1806.
84. Simon R,. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
85. O'Hagan A, Stevens JW,. Bayesian assessment of sample size for clinical trials of cost-effectiveness. Med Decis Making 2001; 21: 219-230.
86. Graf AC, Posch M, Koenig F,. Adaptive designs for subpopulation analysis optimizing utility functions. Biometric J 2015; 57: 76-89.
87. Simon N, Simon R,. Adaptive enrichment designs for clinical trials. Biostatistics 2013; 14: 613-625.
88. Wang S-J, Hung HMJ, O'Neill RT,. Adaptive patient enrichment designs in therapeutic trials. Biometric J 2009; 51: 358-374.
89. Cheung YK,. Dose finding by the continual reassessment method, Boca Raton, FL: Chapman and Hall, 2011.
90. Simes RJ,. Application of statistical decision theory to treatment choices: implications for the design and analysis of clinical trials. Stat Med 1986; 5: 411-420.
91. Grieve AP, Krams M,. ASTIN: A Bayesian adaptive dose-response trial in acute stroke. Clin Trial 2005; 2: 340-351.
92. Berry DA, Fristedt B,. Bandit problems: sequential allocation of experiments, London: Chapman and Hall, 1985.
93. Gittins J,. Multi-armed bandit allocation indices, Chichester: John Wiley, 1989.
94. Gittins JC, Weber R, Glazebrook KD,. Multi-armed bandit allocation indices, Hoboken, NJ: John Wiley & Sons, 2011.
95. Chaloner K, Church T, Louis TA, et al. Graphical elicitation of a prior distribution for a clinical trial. J Royal Stat Soc Ser D (The Statistician) 1993; 42: 341-353.
96. Kadane J, Wolfson LJ,. Experiences in elicitation. J Royal Stat Soc: Series D (The Statistician) 1998; 47: 3-19.
97. O'Hagan A,. Eliciting expert beliefs in substantial practical applications. J Royal Stat Soc: Ser D (The Statistician) 1998; 47: 21-35.
98. Blanck TJJ, Conahan TJ, Merin RG, et al.Being an expert. In: Kadane JB, (ed). Bayesian methods and ethics in a clinical trial design, New York: Wiley, 1996, pp. 159-162.
99. Kinnersley N, Day S,. Structured approach to the elicitation of expert beliefs for a Bayesian-designed clinical trial: a case study. Pharm Stat 2013; 12: 104-113.
100. Parmigiani G, Inoue L,. Decision theory: principles and approaches, Chichester: Wiley, 2009.
101. Lindley DV,. Making decisions, Philadelphia: Wiley, 1971.
102. Emrich LJ, Sedransk N, Whether to participate in a clinical trial: The patient's view. In: Kadane JB, (eds). Bayesian methods and ethics in a clinical trial design, New York: Wiley, 1996, pp. 267-305.